MaxCyte, Inc. Share Price Nasdaq

Equities

MXCT

US57777K1060

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 27/06/2024 BST 5-day change 1st Jan Change
4 USD +0.50% Intraday chart for MaxCyte, Inc. -3.85% -14.89%
Sales 2024 * 36.42M 2.88B Sales 2025 * 46.63M 3.69B Capitalization 426M 33.68B
Net income 2024 * -48M -3.8B Net income 2025 * -45M -3.56B EV / Sales 2024 * 7.58 x
Net cash position 2024 * 150M 11.84B Net cash position 2025 * 120M 9.5B EV / Sales 2025 * 6.55 x
P/E ratio 2024 *
-8.92 x
P/E ratio 2025 *
-9.67 x
Employees 143
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.6%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.50%
1 week-3.85%
Current month-10.71%
1 month-11.89%
3 months-7.41%
6 months-10.51%
Current year-14.89%
More quotes
1 week
3.93
Extreme 3.93
4.32
1 month
3.93
Extreme 3.93
5.26
Current year
3.57
Extreme 3.57
5.55
1 year
2.45
Extreme 2.45
5.55
3 years
2.45
Extreme 2.45
17.44
5 years
1.63
Extreme 1.63
17.44
10 years
1.63
Extreme 1.63
17.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 -
Director of Finance/CFO 54 26/03/23
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 30/11/22
Director/Board Member 71 30/04/06
Director/Board Member 68 29/02/04
More insiders
Date Price Change Volume
27/06/24 4 +0.50% 352,592
26/06/24 3.98 -2.69% 449,239
25/06/24 4.09 -2.39% 354,007
24/06/24 4.19 -1.18% 517,688
21/06/24 4.24 +1.92% 651,219

Delayed Quote Nasdaq, June 27, 2024 at 09:00 pm

More quotes
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.072 USD
Average target price
6.94 USD
Spread / Average Target
+70.44%
Consensus